Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

NCT01046487 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )
DRUG: Imatinib mesylate, Cyclophosphamide (Dosing level 2)
DRUG: Imatinib mesylate, Cyclophosphamide (Dosing level 3)
PROCEDURE: Blood sampling

Sponsor

Centre Oscar Lambret